Cytokine production in patients with cirrhosis and TLR4 polymorphisms

doi:10.3748/wjg.v20.i46.17516

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 46

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6022)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

342

WORD

397

HTML

2820

Figures (1-1)

201

Tables (1-5)

154

Sum=3914

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

921

Download

1187

Sum=2108

Dec 14, 2014 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Dec 14, 2014; 20(46): 17516-17524
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17516

Table 1 Clinical and analytical characteristics of patients with TLR4 polymorphisms and wild-type patients n (%)

	Polymorphisms (n = 9)	Wild-type (n = 10)	P value
Age (yr)	63.2 (40-78)	61.0 (42-79)	0.93
Sex (male/female)	6 (67)/3 (33)	6 (60)/4 (40)	1.00
Etiology (alcohol/HCV/alcohol + HCV/other)	3 (33)/3 (33)/2 (22)/1 (11)	5 (50)/2 (20)/3 (30)/0 (0)	0.5
Child-Pugh score	7 (5-9)	6 (5-8)	0.49
MELD score	11 (6-16)	12 (6-18)	0.62
Serum bilirubin (μmol/L)	17.0 (7-41)	27.5 (9-60)	0.56
Serum albumin (g/L)	32.8 (22.7-49.4)	35.9 (30.0-43.9)	0.34
INR	1.10 (1.01-1.48)	1.22 (0.96-1.39)	0.68
Blood total leukocyte count (× 10⁹/L)	5.89 (2.75-11.48)	5.67 (3.84-8.57)	0.93
Blood neutrophil count (× 10⁹/L)	3.30 (2.00-7.78)	3.21 (1.61-5.63)	0.74
Blood monocyte count (× 10⁹/L)	0.59 (0.20-0.98)	0.66 (0.38-1.00)	0.46
Blood lymphocyte count (× 10⁹/L)	1.00 (0.38-2.15)	1.41 (0.35-2.22)	0.39
Present ascites	3 (33)	3 (30)	1.00
Diuretics	6 (67)	9 (90)	0.30
Beta-blockers	4 (44)	5 (50)	1.00
Norfloxacin prophylaxis	5 (55)	4 (40)	0.65

HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; INR: International normalized ratio.

Table 2 Data of previous complications of cirrhosis in patients with TLR4 polymorphisms and wild-type patients n (%)

	Polymorphisms (n = 9)	Wild-type (n = 10)	P value
Previous ascites	9 (100)	10 (100)	1.00
Previous variceal bleeding	4 (44)	2 (20)	0.35
Previous bacterial infections	8 (89)	5 (50)	0.14
Number of infections/patient	2.0 (0-4)	0.5 (0-5)	0.14
Previous SBP	5 (55)	3 (30)	0.37
Previous hepatic encephalopathy	7 (78)	2 (20)	0.02
Number of episodes of encephalopathy	17	8
Number of episodes of encephalopathy/patient	1 (0-5)	0 (0-7)	0.03
Degree of encephalopathy (episodes) 1/2/3/4	5/9/1/2	3/4/0/1
Degree of encephalopathy¹	2.0 (1-4)	1.9 (1-4)	0.74

¹Median (range) of the degree of hepatic encephalopathy in patients with this complication. SBP: Spontaneous bacterial peritonitis.

Table 3 Spontaneous and stimulated cytokine production by peripheral blood cells in healthy donors and all patients with cirrhosis

	Healthy donors (n = 5)	All patients with cirrhosis (n = 19)	P value
Spontaneous TNF-α (pg/mL)	< 30	602.4 (96.1-3920.1)	0.001
TNF-α after LPS (pg/mL)	1693 (1185-3709)	2904 (931-5078)	0.150
TNF-α after LTA (pg/mL)	638.3 (49.7-1958)	2440 (241-4798)	0.006
Spontaneous IL-6 (pg/mL)	< 10	1537.8 (172.0-26053.9)	0.001
IL-6 after LPS (pg/mL)	20493 (19499-23042)	30219 (1362-32680)	0.006
IL-6 after LTA (pg/mL)	22157 (17390-27010)	30165 (3269-32707)	0.005
Spontaneous IL-10 (pg/mL)	< 30	43.6 (6.5-318.1)	0.210
IL-10 after LPS (pg/mL)	1309 (590.2-1578)	939.9 (120.8-2100)	0.890
IL-10 after LTA (pg/mL)	499.3 (268.7-816.9)	800.4 (80.72-2077)	0.150

TNF-α: Tumour necrosis factor-alpha; LPS: Lipopolysaccharide; LTA: Lipoteichoic acid; IL: Interleukin.

Table 4 Increment in cytokine production expressed as stimulated/spontaneous production fold change in patients with cirrhosis and TLR4 polymorphisms and wild-type patients

	Polymorphisms (n = 9)	Wild-type (n = 10)	P value
Increment TNF-α after LPS	5.3 (1.0-17.4)	3.8 (1.1-17.0)	0.280
Increment TNF-α after LTA	6.5 (1.2-14.4)	2.7 (0.2-5.1)	0.040
Increment IL-6 after LPS	26.0 (14.7-189.9)	3.3 (1.1-17.0)	< 0.001
Increment IL-6 after LTA	35.2 (15.4-183.6)	3.0 (1.2-25.6)	< 0.001
Increment IL-10 after LPS	37.8 (9.3-185.1)	6.3 (0.5-143.9)	0.006
Increment IL-10 after LTA	32.0 (11.3-70.4)	3.7 (1.0-23.7)	0.002

TNF-α: Tumour necrosis factor-alpha; LPS: Lipopolysaccharide; LTA: Lipoteichoic acid; IL: Interleukin.

Table 5 Spontaneous and stimulated cytokine production by peripheral blood cells in patients with cirrhosis not treated with norfloxacin

	Polymorphisms (n = 4)	Wild-type (n = 6)	P value
Spontaneous TNF-α (pg/mL)	464.3 (223.6-3920.1)	813.1 (591-1573)	0.25
TNF-α after LPS (pg/mL)	3166 (931.8-5078)	2936 (1272-4547)	0.76
TNF-α after LTA (pg/mL)	2766 (2291-4798)	1927 (241.3-4455)	0.17
Spontaneous IL-6 (pg/mL)	699.4 (320.8-1145.6)	5540 (1538-26053.9)	< 0.001
IL-6 after LPS (pg/mL)	27880 (19100-30070)	29000 (24960-32670)	0.47
IL-6 after LTA (pg/mL)	29660 (27970-30290)	29860 (3269-32170)	1.00
Spontaneous IL-10 (pg/mL)	13.2 (6.5-39.1)	135.6 (36.2-318.1)	0.02
IL-10 after LPS (pg/mL)	949.5 (655-1474)	1467 (334.5-2100)	0.35
IL-10 after LTA (pg/mL)	606.8 (376-1234)	897.6 (86.66-1530)	0.91

TNF-α: Tumour necrosis factor-alpha; LPS: Lipopolysaccharide; LTA: Lipoteichoic acid; IL: Interleukin.

Citation: Nieto JC, Sánchez E, Román E, Vidal S, Oliva L, Guarner-Argente C, Poca M, Torras X, Juárez C, Guarner C, Soriano G. Cytokine production in patients with cirrhosis and TLR4 polymorphisms. World J Gastroenterol 2014; 20(46): 17516-17524
URL: https://www.wjgnet.com/1007-9327/full/v20/i46/17516.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i46.17516